DV
Dividend Vision

DYN — Dyne Therapeutics, Inc.

Dyne Therapeutics, Inc. (DYN)

Total return is 7.5% over the past 5.9 years, 143.5 points behind SPY at 151.0%. Its deepest 1-year drawdown was 39.9%.

This is a single-stock equity holding in Dyne Therapeutics, a biotechnology company, rather than a diversified ETF. The holding does not currently pay distributions and therefore has no yield profile or regular income component. The stock may appeal primarily to growth-oriented investors seeking exposure to the therapeutic development sector, rather than to income-focused investors.

DYN key facts

Asset type
Stock
Asset class
Equity
Inception date
09/17/2020
Distribution frequency
None
Last close
$25.70
Market cap
$4,799,383,552
Average volume
1684487.0
Beta
1.084
Payout ratio
0.0
Forward P/E
0.0
EPS
$-3.26